NASDAQ:RVMDW Revolution Medicines (RVMDW) Stock Price, News & Analysis $10.13 +0.31 (+3.16%) As of 11:01 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsNews and TrendsSEC Filings About Revolution Medicines Stock (NASDAQ:RVMDW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Revolution Medicines alerts:Sign Up Key Stats Today's Range$10.01▼$10.4650-Day Range$8.41▼$13.2652-Week Range$0.23▼$13.44Volume23,918 shsAverage Volume104,800 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies. Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants. These programs are being evaluated as both monotherapies and in combination with existing treatments to determine safety, tolerability and preliminary efficacy in patients with solid tumors. Headquartered in Redwood City, California, the company was founded in 2015 and completed its initial public offering in August 2020. Its research and development operations leverage structure-based drug design and proprietary chemistry platforms to accelerate the discovery of next-generation RAS pathway inhibitors. Under the leadership of President and Chief Executive Officer Roger DiPiazza, Revolution Medicines has established collaborations with leading biopharmaceutical partners to extend its global reach and advance its oncology pipeline. The company continues to explore novel therapeutic opportunities aimed at improving outcomes for patients with RAS-driven cancers worldwide.AI Generated. May Contain Errors. Read More Receive RVMDW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RVMDW Stock News HeadlinesRevolution Medicines' Daraxonrasib Secures FDA Breakthrough Designation In Pancreatic CancerSeptember 15, 2026 | rttnews.comRevolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley SaysSeptember 10, 2026 | finance.yahoo.comElon gets it. Do you?Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and Merck added $43 billion to its market cap on the same news. Porter & Co. says AI-driven drug discovery and automated labs are cutting development timelines by up to 80% and lifting early clinical success rates to 90%, fueling what they call biotech's Ignition Point.September 24 at 1:00 AM | Porter & Company (Ad)Morgan Stanley initiates coverage of Revolution Medicines with overweightSeptember 10, 2026 | msn.comRevolution a new overweight at Morgan Stanley on RAS-targeted oncology franchiseSeptember 10, 2026 | msn.comRevolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading JournalSeptember 5, 2026 | finance.yahoo.comAnalysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)September 4, 2026 | theglobeandmail.comRevolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough?September 4, 2026 | finance.yahoo.comSee More Headlines RVMDW Stock Analysis - Frequently Asked Questions How have RVMDW shares performed this year? Revolution Medicines' stock was trading at $0.9399 at the beginning of the year. Since then, RVMDW stock has increased by 937.3% and is now trading at $9.75. How do I buy shares of Revolution Medicines? Shares of RVMDW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/24/2026Next Earnings (Estimated)11/11/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 RVMDW's financial health is in the Green zone, according to TradeSmith. RVMDW has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RVMDW CIK1628171 Webwww.revmed.com Phone650-481-6801FaxN/AEmployees378Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableN/A BetaN/A Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:RVMDW) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredWall Street Legend: “I've discovered a fatal flaw built into Elon's AI model”Wall Street veteran Marc Chaikin says he's found a fatal flaw built into Elon Musk's AI model and every fronti...Chaikin Analytics | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredCongress Passes Landmark Digital Asset Law Wall Street Is WatchingThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
